skip to content

Clinical Trials

MainTitle

A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant

This study has been completed
Sponsor
Glaxo Wellcome


Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier
NCT00002284

First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: February 1995
History of Changes
Purpose

Purpose

To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.

Condition Intervention
Lymphoma, Non-Hodgkin
HIV Infections

Drug : Zidovudine

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Eligibility

Eligibility

Ages Eligible for Study: 12 Years to 50 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Exclusion Criteria
Co-existing Condition:
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
Concurrent Medication:
Excluded:

  • Other anti-retroviral agents.

  • Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
    Patients must be:
  • HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.
  • At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).
  • Also patient must fall into one of the following categories:
  • Have an HIV seronegative identical twin to serve as a bone marrow donor.
  • Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.
  • Be a good risk candidate for bone marrow transplant.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002284

Locations

United States, Maryland
Johns Hopkins Hemapheresis Treatment Ctr
Baltimore, Maryland, United States, 21205

Sponsors and Collaborators

Glaxo Wellcome
More Information

More Information


Responsible Party: Glaxo Wellcome  
ClinicalTrials.gov Identifier: NCT00002284   History of Changes  
Other Study ID Numbers: 014A  
  006  
Study First Received: November 2, 1999  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Lymphoma, Large-Cell
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Zidovudine
Bone Marrow Transplantation

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Lymphoma, Non-Hodgkin
Zidovudine

ClinicalTrials.gov processed this data on October 16, 2017
This information is provided by ClinicalTrials.gov.